Externally-led meetings of this kind occupy a distinctive position in the regulatory landscape. While the FDA convenes its own patient-focused meetings for selected conditions, patient organizations can also host externally-led versions that follow the same structured approach, inviting patients, caregivers, clinicians, drug developers, and regulators to a common forum. In this case, the Association has confirmed that drug developers, the FDA, and other stakeholders will be in attendance, meaning that the testimony gathered during the proceedings will reach precisely the audiences capable of acting on it. The goal is not simply to document suffering but to convert personal narratives into structured evidence that can inform clinical trial design, endpoint selection, benefit-risk assessment, and regulatory decision-making for years to come.

Non-cystic fibrosis bronchiectasis is a chronic lung disease characterized by persistent inflammation and chronic infection, in which the airways become abnormally widened, thickened, or scarred. This structural damage impairs the lungs’ ability to clear mucus, creating a vicious cycle in which retained secretions harbor bacteria, bacterial colonization drives further inflammation, and ongoing inflammation deepens the airway injury. Patients typically experience chronic cough, copious sputum production, recurrent respiratory infections, breathlessness, and profound fatigue. Exacerbations, the acute worsening episodes that punctuate the disease’s course, can force hospitalization and are associated with accelerated loss of lung function over time. The daily burden of managing airway clearance, antibiotics, and the psychological weight of a lifelong condition is substantial and often invisible to those outside the patient community.

For decades, the disease was considered rare, a classification that shaped nearly every aspect of the research and treatment environment surrounding it. Rare disease status typically means small patient populations, fragmented clinical data, limited commercial incentives for drug development, and lengthy diagnostic delays. As the Association notes, however, the picture has changed considerably in recent years. Growing awareness, expanded research activity, and advances in imaging, particularly high-resolution computed tomography, have dramatically improved the ability of clinicians to recognize and characterize the disease. Epidemiological studies across multiple countries have suggested that bronchiectasis is more common than previously appreciated, particularly among older adults, and the condition is now recognized more widely throughout the medical community. This shift in recognition has laid the groundwork for the therapeutic progress now beginning to emerge.

That progress reached a watershed moment in 2025, when the first FDA-approved treatment for non-cystic fibrosis bronchiectasis became available. The approval ended a long era in which patients and their physicians had to rely entirely on off-label approaches, borrowed from cystic fibrosis care or general respiratory medicine, to manage a disease with its own distinct biology. Yet the Association is careful to frame this milestone as a beginning rather than an endpoint. Many people with the condition still face delays in diagnosis, limited access to specialized care, and persistent difficulties managing the disease’s daily impact. A single approved therapy, however significant, cannot address the full spectrum of patient needs, and the Association’s announcement makes clear that significant unmet needs remain across the community.

The planned meeting has been structured around three explicit objectives. First, it aims to enhance understanding of how living with non-cystic fibrosis bronchiectasis impacts daily life experiences, capturing dimensions of the disease that conventional clinical measures often miss. Second, it seeks to capture diverse perspectives from across the NCFB community in order to foster timely and effective therapy development, ensuring that the pipeline reflects the heterogeneity of the patient population rather than a narrow slice of it. Third, it intends to inform regulatory decision-making with insights on current care and treatment benefit needs, giving reviewers and policymakers a grounded picture of what patients would consider meaningful improvement. Together, these objectives reflect a maturing philosophy in drug development: that patient input is not anecdote but data.

Elisha Malanga, Executive Director of the Bronchiectasis and NTM Association, emphasized the significance of the moment in a statement accompanying the announcement. The first FDA-approved treatment for the disease marked an important milestone, she said, but significant unmet needs remain, and the daily burden of the disease continues to affect many people living with the condition. She described the initiative as an important opportunity to ensure that the voices of people living with non-cystic fibrosis bronchiectasis are heard by the FDA, researchers, and treatment developers, and she noted that by sharing their experiences, challenges, and priorities, community members can help shape a deeper understanding of the disease and inform the development of future treatments that address what matters most to them.

The meeting itself is proposed for late 2027, a timeline that gives the Association and its partners ample opportunity to prepare. Crucially, the event will include a virtual element, a design choice intended to ensure accessibility for all attendees regardless of geography, health status, or mobility. This consideration matters enormously for a lung disease community in which many patients manage chronic infection and fatigue that can make travel difficult or risky. The Association has committed to engaging a wide array of NCFB community stakeholders in support of the initiative, and additional information about the meeting, including details on participation, will be released at a later date. The extended runway also allows time for structured pre-meeting surveys and outreach, tools commonly used in patient-focused drug development to reach patients who cannot attend live sessions.

The broader significance of the announcement extends beyond a single disease community. Patient-focused drug development has become one of the most consequential shifts in modern regulatory science, reflecting a growing consensus that clinical trial endpoints must align with outcomes patients actually value. For a condition like non-cystic fibrosis bronchiectasis, where exacerbation frequency, symptom burden, and quality of life are central to the patient experience, systematically collected patient input can help sponsors design trials that measure what matters, potentially shortening development timelines and improving the odds that approved therapies deliver tangible benefit. It can also help regulators weigh benefits and risks in ways that reflect real-world priorities rather than surrogate measures alone.

For the bronchiectasis and NTM community, the announcement represents both recognition and momentum. An organization founded to serve patients with two closely related and long-neglected conditions is now convening the full machinery of drug development, from regulators to industry, around the testimony of the people who live with the disease every day. If the meeting fulfills its stated aims, the experiences shared in late 2027 could echo through trial protocols, regulatory reviews, and ultimately treatment options for a patient population that has waited far longer than most for therapies designed specifically for them. Additional details about the meeting will be announced by the Association as planning progresses.

Subject of Research: An externally-led patient-focused drug development meeting for non-cystic fibrosis bronchiectasis announced by the Bronchiectasis and NTM Association.

Article Title: Bronchiectasis and NTM Association announces Externally-Led Patient-Focused Drug Development meeting for non-cystic fibrosis bronchiectasis

Article References: Bronchiectasis and NTM Association announces Externally-Led Patient-Focused Drug Development meeting for non-cystic fibrosis bronchiectasis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: bronchiectasis, NTM, NCFB, PFDD, FDA, drug development, patient advocacy, lung disease, clinical research, regulatory decision-making, COPD Foundation, rare disease

The clinical stakes are considerable. The World Health Organization does not publish a global prevalence report for NTM, so estimates come from national cohort studies and systematic reviews, and these consistently show rising incidence and prevalence over recent decades, with a particularly pronounced burden in low-income nations. The M. avium complex remains the predominant species in most countries. These bacteria thrive in humid environments, colonizing showers, hot tubs, thermal springs, and ventilation systems, and people typically acquire infection by inhaling contaminated aerosols. Their capacity to form biofilms allows them to colonize medical devices and water distribution systems, and infections have even followed tattoos, piercings, and cosmetic procedures. While person-to-person transmission is uncommon, evidence suggests potential transmission between cystic fibrosis patients and in specific healthcare settings, adding a troubling dimension to an already difficult problem.

Tigecycline itself is a derivative of minocycline and belongs to the glycylcycline class, engineered to overcome many of the mechanisms that render older tetracyclines ineffective. Its mechanism of action is elegant in its simplicity: the molecule binds to the 30S subunit of the bacterial ribosome, blocking the entry of aminoacyl-tRNA into the A site and thereby halting protein synthesis. Against Gram-positive and Gram-negative bacteria alike, and against certain mycobacteria, this broad-spectrum activity has made tigecycline a valuable last-resort agent. But mycobacteria are formidable adversaries. Their lipid-rich cell walls, packed with mycolic acids and studded with only sparse porin channels, form a permeability barrier that limits antibiotic penetration, and they deploy an arsenal of active resistance mechanisms on top of this passive defense.

The review’s authors searched Scopus, PubMed, the Virtual Health Library, SciELO, Web of Science, and LILACS between September and December 2025, screening 42 potentially relevant articles and ultimately including 28 in their analysis. The evidence they compiled paints a nuanced picture. Early studies reported consistently low minimum inhibitory concentrations, or MIC values, for tigecycline against the M. abscessus complex, with MIC50 values at or below 0.12 micrograms per milliliter and MIC90 values of 0.25 micrograms per milliliter in rapidly growing mycobacteria including M. abscessus, M. chelonae, and M. fortuitum. More recent work, however, has documented heterogeneity, with some clinical isolates showing resistance or reduced susceptibility despite the drug’s initially promising in vitro profile, suggesting that genetic determinants play a substantial role in modulating susceptibility.

One of the most striking findings concerns MabTetX, a flavin-dependent monooxygenase encoded by the gene MAB_1496c that serves as the principal tetracycline resistance determinant in M. abscessus. This enzyme degrades classical tetracyclines, and its expression increases in the presence of tetracycline and doxycycline. Crucially, however, tigecycline does not induce MabTetX expression and is far less affected by the enzyme’s activity, which explains why the drug retains activity against isolates resistant to older tetracyclines. This structural advantage, though, does not prevent resistance from emerging through entirely different adaptive pathways, a theme that runs throughout the review’s molecular analysis.

That adaptive machinery centers on WhiB7, a transcription factor that functions as the master regulator of the intrinsic antibiotic stress response in mycobacteria. When activated, WhiB7 induces a suite of resistance-associated genes including erm(41), eis2, hflX, and members of the ABCF family, promoting adaptive resistance to several antimicrobial classes. Experimental studies showed that deleting whiB7 significantly increases susceptibility to tigecycline, while its expression raises the MIC. The review also highlights the sigH-rshA axis: mutations in rshA, which encodes an anti-sigma factor, disrupt the interaction between RshA and the sigma factor SigH, leading to SigH overexpression and extensive transcriptional reprogramming characterized by reduced ribosomal protein synthesis, enhanced stress adaptation, and increased antibiotic tolerance. A spontaneous M. abscessus mutant carrying an rshA mutation exhibited tigecycline resistance, cross-resistance to imipenem, and a modest growth defect, and subsequent work linked the dysregulated stress response to decreased ribosomal gene expression and transient resistance induced by heat stress.

Efflux pumps add yet another layer of defense. Members of the MmpL family, particularly MmpL5, together with ABCF and Major Facilitator Superfamily transporters, actively export tigecycline from the bacterial cell, driven by ATP hydrolysis. Transcriptomic analyses demonstrated that just 24 hours of exposure to tigecycline significantly induces the expression of these efflux systems, reducing intracellular drug concentrations and limiting binding to the ribosomal target. Notably, many of these transporters appear to be regulated directly or indirectly by WhiB7, underscoring how tightly interconnected the resistance pathways are. Efflux pump inhibitors offer a tantalizing countermeasure: verapamil, the most extensively studied, has been shown to reduce the activity of multiple efflux pumps and potentially lower tigecycline MIC values in some isolates, while CCCP dissipates the proton motive force that powers proton-dependent pumps, and reserpine directly blocks MFS transporters. However, most evidence for these inhibitors comes from combinations with other antimicrobials such as bedaquiline, clofazimine, rifampicin, and macrolides, and their clinical application remains experimental.

In sharp contrast to the rapid growers, slow-growing species present a fundamentally different problem. M. avium, M. intracellulare, and M. kansasii consistently exhibit MIC values exceeding 4 micrograms per milliliter, with reported MIC50 and MIC90 values of at least 8 micrograms per milliliter in some studies. Here, reduced susceptibility appears rooted in intrinsic characteristics, particularly the highly lipid-rich, poorly permeable cell envelope and lower metabolic activity, rather than the adaptive regulatory mechanisms so extensively characterized in M. abscessus. A systematic review of 89 studies confirmed that tigecycline demonstrates greater activity against rapidly growing NTM, while evidence supporting its efficacy in slow-growing species remains limited. The review’s authors conclude that tigecycline is best positioned as a component of combination regimens for rapid-growing NTM, particularly multidrug-resistant isolates, and should rarely, if ever, be used as monotherapy given the growing recognition of adaptive resistance mechanisms.

Significant caveats temper these conclusions. Most available studies rely on in vitro susceptibility testing with relatively small collections of clinical isolates focused mainly on the M. abscessus complex, and substantial methodological variability in broth microdilution protocols, culture media, incubation periods, and isolate selection makes direct comparison across studies difficult. Isolates from different geographic regions may carry regional genetic diversity that further influences susceptibility profiles. Perhaps most critically, standardized clinical breakpoints for tigecycline have not yet been established, which restricts the translation of MIC data into clinical decision-making. Other proposed determinants, such as mutations in the gene MAB_3542c and in rpsA, have not been consistently reproduced, and biofilm formation’s contribution to tigecycline resistance remains poorly quantified.

Looking forward, the review’s authors call for multicenter studies with larger, geographically diverse isolate collections and standardized susceptibility testing protocols. Integrated genomic and transcriptomic approaches will be essential to identify novel resistance determinants and to determine whether the mechanisms described in M. abscessus are conserved across other NTM species. Establishing robust correlations between in vitro susceptibility, molecular mechanisms, and actual clinical outcomes will be critical for defining clinically relevant breakpoints and optimizing tigecycline-based regimens. For now, the message is one of cautious optimism: a drug once considered mainly for other resistant infections may become a cornerstone of therapy against some of the most treatment-refractory mycobacteria, provided clinicians deploy it wisely and researchers close the gaps that still separate laboratory promise from bedside certainty.

Subject of Research: Mechanisms and prevalence of tigecycline resistance in nontuberculous mycobacteria

Article Title: A review of tigecycline resistance in nontuberculous mycobacteria

Article References: Moura, C. D. S., da Silva, W. M. V., & Ramos, J. P. (2026). A review of tigecycline resistance in nontuberculous mycobacteria. Molecular Biology Reports, 53(1), Article 1637. https://doi.org/10.1007/s11033-026-12747-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12747-1

Keywords: tigecycline, nontuberculous mycobacteria, Mycobacterium abscessus, antimicrobial resistance, efflux pumps, WhiB7, MabTetX, SigH-RshA, minimum inhibitory concentration, glycylcyclines, combination therapy, drug-resistant bacteria